Editorial: Following nero: Fiddle while Rome burns, or is there a better way?

Thorax

Volumn 66, Issue 5, 2011, Pages 367-

  Bush, Andrew ^a   Pavord, Ian ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PARACETAMOL; PLACEBO;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; ENVIRONMENTAL FACTOR; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG DISEASE; LUNG FUNCTION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SOCIAL PROBLEM; SOCIAL PSYCHOLOGY; SPIROMETRY; WHISKEY; ACUTE DISEASE; NOMENCLATURE; NOTE;

ACUTE DISEASE; ASTHMA; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TERMINOLOGY AS TOPIC;

EID: 79954999104     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2011.160861     Document Type: Editorial

References (6)

1. FitzGerald JM. Targeting lung attacks. Thorax 2011;66:365-66.
2. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
3. Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34.
4. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV (1) decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
5. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30:52-6.
6. O'Byrne PM, Pedersen S, Lamm CJ, et al; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.